Dejan B Budimirovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1083221/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment. Pediatrics, 2017, 139, S194-S206.	2.1	186
2	What Can We Learn about Autism from Studying Fragile X Syndrome?. Developmental Neuroscience, 2011, 33, 379-394.	2.0	154
3	Arbaclofen in fragile X syndrome: results of phase 3 trials. Journal of Neurodevelopmental Disorders, 2017, 9, 3.	3.1	135
4	Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. Journal of Neurodevelopmental Disorders, 2017, 9, 14.	3.1	123
5	Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal of Neurodevelopmental Disorders, 2017, 9, 7.	3.1	99
6	Autism spectrum disorder in Fragile X syndrome: Differential contribution of adaptive socialization and social withdrawal. American Journal of Medical Genetics, Part A, 2006, 140A, 1814-1826.	1.2	88
7	Mosaic <i>FMR1</i> deletion causes fragile X syndrome and can lead to molecular misdiagnosis: A case report and review of the literature. American Journal of Medical Genetics, Part A, 2008, 146A, 1358-1367.	1.2	88
8	Parental reports on early language and motor milestones in fragile X syndrome with and without autism spectrum disorders. Developmental Neurorehabilitation, 2013, 16, 58-66.	1.1	79
9	A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments. Brain Sciences, 2020, 10, 694.	2.3	54
10	Best Practices in Fragile X Syndrome Treatment Development. Brain Sciences, 2018, 8, 224.	2.3	37
11	Clinical Development of Targeted Fragile X Syndrome Treatments: An Industry Perspective. Brain Sciences, 2018, 8, 214.	2.3	29
12	Fragile X Syndrome: From Molecular Aspect to Clinical Treatment. International Journal of Molecular Sciences, 2022, 23, 1935.	4.1	27
13	Profiling early socio-communicative development in five young girls with the preserved speech variant of Rett syndrome. Research in Developmental Disabilities, 2012, 33, 1749-1756.	2.2	26
14	Fragile X syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials. Translational Neuroscience, 2017, 8, 7-8.	1.4	26
15	Genomic studies in fragile X premutation carriers. Journal of Neurodevelopmental Disorders, 2014, 6, 27.	3.1	24
16	Peculiarities in the gestural repertoire: An early marker for Rett syndrome?. Research in Developmental Disabilities, 2012, 33, 1715-1721.	2.2	21
17	Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis. Brain Sciences, 2020, 10, 629.	2.3	21
18	Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study. International Journal of Molecular Sciences, 2021, 22, 2863.	4.1	19

Dejan B Budimirovic

#	Article	IF	CITATIONS
19	Sleep problems in fragile X syndrome: Crossâ€sectional analysis of a large clinicâ€based cohort. American Journal of Medical Genetics, Part A, 2022, 188, 1029-1039.	1.2	18
20	Autism in Genetic Intellectual Disability. , 2008, , 81-108.		17
21	Emergence of Developmental Delay in Infants and Toddlers With an <i>FMR1</i> Mutation. Pediatrics, 2021, 147, .	2.1	16
22	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome. Brain Sciences, 2020, 10, 899.	2.3	15
23	Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Scientific Reports, 2015, 5, 8902.	3.3	10
24	Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study. Frontiers in Pharmacology, 2021, 12, 757825.	3.5	9
25	Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study. Brain Sciences, 2022, 12, 314.	2.3	7
26	Neurobehavioral features and targeted treatments in fragile X syndrome: Current insights and future directions. Engrami, 2015, 37, 5-26.	0.1	6
27	Height and BMI in fragile X syndrome: AÂlongitudinal assessment. Obesity, 2022, 30, 743-750.	3.0	6
28	Fragile X-Associated Disorders in Serbia: Baseline Quantitative and Qualitative Survey of Knowledge, Attitudes and Practices Among Medical Professionals. Frontiers in Neuroscience, 2018, 12, 652.	2.8	3
29	Increasing Interest in Child and Adolescent Psychiatry Through a Structured Tutorial Program. Academic Psychiatry, 2020, , 1.	0.9	3
30	FMR1 gene mutations cause neurodevelopmental-degenerative disorders: Importance of fragile X testing in Serbia. Vojnosanitetski Pregled, 2016, 73, 1089-1093.	0.2	3
31	The Urgent Need for Molecular Imaging to Confirm Target Engagement for Clinical Trials of Fragile X Syndrome and Other Subtypes of Autism Spectrum Disorder. Archives of Neuroscience, 2019, 6, .	0.3	3
32	Can a Neurosteroid Ameliorate Fragile X-Associated Tremor/Ataxia Syndrome?. Neurotherapeutics, 2017, 14, 1070-1072.	4.4	2
33	Challenges in Translating Therapeutic Frontiers in Clinical Trials: Where Are We Now and What's Next?. Madridge Journal of Neuroscience, 2017, 1, 1-3.	0.0	1
34	MEASUREMENT OF CEREBRAL EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 5 IN AUTISM SPECTRUM DISORDER AND FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, S257.	0.5	1
35	Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries?. Yale Journal of Biology and Medicine, 2021, 94, 559-571.	0.2	1